Health IT

Physicians are being warned about indemnification clauses in contracts that can shift immense liability. Here's what doctors need to know to avoid financial ruin.

New long-term data for UPLIZNA and TAVNEOS show sustained disease control and reduced steroid use, offering a tangible difference for rare disease patients.

Insulet's latest Omnipod 5 enhancements are more than a software update; they're a strategic move in the diabetes tech race. Here's what it means.

Perspective Therapeutics is testing a potent alpha-particle therapy for meningioma, the most common brain tumor, offering a new option where surgery fails.

A new report from Garmin offers more than just stats on running and cycling. It's a window into our collective habits, motivations, and the powerful feedback loop between technology and human behavior.

MiniMed and Abbott are partnering on a dual glucose-ketone sensor, a move that could shift diabetes care from crisis management to proactive DKA prevention.

Freshly independent, MiniMed reports record sales and a robust product pipeline, signaling a focused strategy to dominate the competitive diabetes tech market.

As corporate interests reshape medicine, a leading physician's call for stewardship revives a debate on the soul of healthcare. Can timeless values survive?

A new integration aims to make enterprise AI trustworthy by teaching it business context, transforming messy unstructured data into a strategic asset.

A call for research on vaccine side effects exposes a deeper crisis: the collapse of public trust in science. Can rigorous data heal a polarized nation?

Bluejay Diagnostics secures critical funding to advance its rapid sepsis test, extending its cash runway but raising questions about shareholder dilution.

Alani Skin MD's "Best Med Spa" award reveals more than local popularity; it's a masterclass in leveraging market trends and customer loyalty.

A pivotal partnership between WeInfuse and Trial IQ leverages AI to bring clinical trials to local infusion centers, signaling a major shift in drug development.

A new study reveals an 'early warning system' in infant guts, offering a window to combat the atopic march before allergies take hold. Is this the future?

Mindray's new Hepatus-Series goes beyond a simple product launch, integrating AI-driven elastography to transform GI diagnostics and challenging market norms.

As psychedelics go mainstream, a new initiative asks a hard question: what about those most harmed by their prohibition? MAPS' latest project is a radical rethink.

By turning 2,792 miles of GPS data into a stop-motion film, a nonprofit is redefining advocacy and inviting the world to run for a cause.

Nephrodite's implantable dialysis system just entered a key FDA program, signaling a major shift in treating kidney failure. Is freedom from the dialysis chair finally in sight?

A delayed financial report and a plea for a trading halt for its own executives place Premier Health under a harsh spotlight, signaling deeper financial distress.

A burgeoning market for cervical dystonia is set for disruption. A pipeline of novel therapies, including oral options, promises to address unmet patient needs.